

Y. Ikeura, et al
U.S.S.N. 09/807,337
Page 2

RECEIVED
CENTRAL FAX CENTER
AUG 09 2006

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1-3. (Cancelled).

4. (Currently amended) A base for a percutaneously absorbing preparation, comprising 10-40% by weight of styrene-isoprene-styrene block copolymer, and/or 2-10% by weight of polyisobutylene, 10-60% by weight of softener, 20-60% by weight of tackifier, 1-10% by weight of hexylene glycol and 0.1-7% by weight of 1-menthol, wherein 10-40% by weight of styrene-isoprene-styrene block copolymer, 2-10% by weight of polyisobutylene, 10-60% by weight of softener and 20-60% by weight of tackifier are essential components, and 1-10% by weight of hexylene glycol and 0.1-7% by weight of 1-menthol are compounded therewith as the components of the base.

5. (Cancelled)

6. (Previously presented) A percutaneously absorbing preparation wherein a pharmaceutical agent is contained as an effective ingredient in the base for a percutaneously absorbing preparation according to claim 4.

7. (Previously Presented) The percutaneously absorbing preparation according to claim 6, wherein the pharmaceutical agent is follicular hormone and/or luteinizing hormone.

8. (Currently amended) The percutaneously absorbing preparation according to claim 7, wherein the follicular hormone is estradiol, estrone, estrin, equilin or equilenin or a derivative thereof and its compounding amount is 0.1-5% by weight.

Y. Ikeura, et al
U.S.S.N. 09/807,337
Page 3

9. (Withdrawn-Currently amended) The percutaneously absorbing preparation according to claim 7, wherein the luteinizing hormone is norethisterone, norethisterone acetate, norethisterone enanthate, or progesterone or a derivative thereof and its compounding amount is 0.5-10% by weight.